upcoming investor conferenceS
Marseille, France, January 4, 2017
Innate Pharma SA (the "Company" - Euronext Paris: FR0010331421 - IPH) today announces that it will be present at four upcoming investor conferences in Q1 2017, where Innate Pharma`s management team, including Mondher Mahjoubi, the newly appointed Chief Executive Officer and Chairman of Innate Pharma`s Executive Board, will provide an overview of the Company.
The four investor conferences in Q1 2017 are:
-
Oddo Midcap Forum - Lyon, France, January 5-6
-
J.P. Morgan 35th Annual Healthcare Conference - San Francisco, CA, USA, January 9-12
-
Leerink Partners 6th Annual Global Healthcare Conference - New York, NY, USA, February 15-16
-
Credit Suisse London One on One Global Healthcare Conference - London, UK, February 28-March 1
Innate Pharma is committed to meet on a regular basis with the financial community. All corporate information on the Company, such as its financial statements or its corporate presentations, is available on the Company`s website in the Investors` section (http://www.innate-pharma.com/en/investors).
About Innate Pharma:
Innate Pharma S.A. is a clinical-stage biotechnology company with a focus on discovering and developing first-in-class therapeutic antibodies that harness the innate immune system to improve cancer treatment and clinical outcomes for patients.
Innate Pharma specializes in immuno-oncology, a new therapeutic field that is changing cancer treatment by mobilizing the power of the body`s immune system to recognize and kill cancer cells.
The Company`s aim is to become a commercial stage biopharmaceutical company in the area of immunotherapy and focused on serious unmet medical needs in cancer. Innate Pharma has pioneered the discovery and development of checkpoint inhibitors to activate the innate immune system. Innate Pharma`s innovative approach has resulted in three first-in-class, clinical-stage antibodies targeting natural killer cell receptors that may address a broad range of solid and hematological cancer indications as well as additional preclinical product candidates and technologies. Targeting receptors involved in innate immunity also creates opportunities for the Company to develop therapies for inflammatory diseases.
The Company`s expertise and understanding of natural killer cell biology have enabled it to enter into major alliances with leaders in the biopharmaceutical industry including AstraZeneca, Bristol-Myers Squibb, Novo Nordisk A/S and Sanofi.
Based in Marseille, France, Innate Pharma has more than 150 employees and is listed on Euronext Paris.